维司力农 AHFS /Drugs.com 国际药品名称 给药途径 口服给药 ATC碼 法律規範
6-[4-(3,4-Dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
CAS号 81840-15-5 Y PubChem CID ChemSpider UNII ChEMBL CompTox Dashboard (EPA ) 化学式 C 22 H 25 N 3 O 4 摩尔质量 395.46 g·mol−1 3D模型(JSmol )
COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)OC
InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
N Key:ZVNYJIZDIRKMBF-UHFFFAOYSA-N
N
维司力农 (INN :vesnarinone)是一种强心剂 。[ 1] 一种混合磷酸二酯酶3抑制剂 和离子通道调节剂,具有适度的、剂量依赖性的正性肌力活性,但负性变时性活性极小。[ 2] 有研究探索了维司力农用于治疗心力衰竭 的安全性。[ 3] [ 4]
参考资料
^ Cavusoglu E, Frishman WH, Klapholz M. Vesnarinone: a new inotropic agent for treating congestive heart failure. Journal of Cardiac Failure. June 1995, 1 (3): 249–257. PMID 9420657 . doi:10.1016/1071-9164(95)90030-6 .
^ Feldman, Arthur M. Clinical characteristics of vesnarinone . Drug Safety. 2004,. 27 Suppl 1. ISSN 0114-5916 . PMID 15293848 . doi:10.2165/00002018-200427001-00002 .
^ Cohn, J. N.; Goldstein, S. O.; Greenberg, B. H.; Lorell, B. H.; Bourge, R. C.; Jaski, B. E.; Gottlieb, S. O.; McGrew, F.; DeMets, D. L.; White, B. G. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators . The New England Journal of Medicine. 1998-12-17, 339 (25). ISSN 0028-4793 . PMID 9854116 . doi:10.1056/NEJM199812173392503 .
^ Feldman, A. M.; Bristow, M. R.; Parmley, W. W.; Carson, P. E.; Pepine, C. J.; Gilbert, E. M.; Strobeck, J. E.; Hendrix, G. H.; Powers, E. R.; Bain, R. P. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group . The New England Journal of Medicine. 1993-07-15, 329 (3). ISSN 0028-4793 . PMID 8515787 . doi:10.1056/NEJM199307153290301 .
外部链接